Corline Biomedical Valuation Multiples

Corline Biomedical Overview

About Corline Biomedical

Corline Biomedical AB offers customers in the medical technology industry and regenerative medicine as well as transplant clinics products to manage immune thrombosis. The company offers a proprietary surface treatment technology, Corline Heparin Surface (CHS), which can be used in combination with all commonly used implant materials such as polymers (plastics) and various metals, but also for equipment where blood circulation occurs outside the body.

Founded

1991

HQ

Employees

13

Website

corline.se

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $2M

EBITDA: ($572K)

EV

$44M

Valuation Multiples

Multiples.vc

Start free trial

Corline Biomedical Financials

Corline Biomedical reported last 12-month revenue of $2M and negative EBITDA of ($572K).

In the same LTM period, Corline Biomedical generated $2M in gross profit, ($572K) in EBITDA losses, and had net loss of ($615K).

Corline Biomedical P&L

In the most recent fiscal year, Corline Biomedical reported revenue of $853K and EBITDA of ($2M).

Corline Biomedical expects next 12-month revenue of XXX and NTM EBITDA of XXX

Corline Biomedical Stock Performance

Corline Biomedical has current market cap of $46M, and enterprise value of $44M.

Corline Biomedical's stock price is $1.80.

Corline Biomedical Valuation Multiples

Corline Biomedical trades at 21.6x EV/Revenue multiple, and (76.4x) EV/EBITDA.

Corline Biomedical Financial Valuation Multiples

As of April 18, 2026, Corline Biomedical has market cap of $46M and EV of $44M.

Equity research analysts estimate Corline Biomedical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Corline Biomedical has a P/E ratio of (74.8x).

Corline Biomedical Margins & Growth Rates

Corline Biomedical's revenue in the last 12 month grew by 225%.

Corline Biomedical's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.

Corline Biomedical's rule of 40 is 520% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Corline Biomedical's rule of X is 1240% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Corline Biomedical Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Corline Biomedical M&A Activity

Corline Biomedical acquired XXX companies to date.

Last acquisition by Corline Biomedical was on XXXXXXXX, XXXXX. Corline Biomedical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Corline Biomedical Investment Activity

Corline Biomedical invested in XXX companies to date.

Corline Biomedical made its latest investment on XXXXXXXX, XXXXX. Corline Biomedical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).